Prolonged progression free survival does not relate to quality of response to treatment with thalidomide in patients with relapsed multiple myeloma (MM)

被引：0
|
作者：
Quach, Hang [1 ]
Prince, Miles H. [1 ]
Mileshkin, Linda [1 ]
Seymour, John F. [1 ]
Westerman, David [1 ,2 ]
Milner, Alvin D. [3 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2718.2718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2718
引用
收藏
页码：798A / 798A
页数：1
相关论文
共 50 条
  • [1] Durable response to thalidomide in relapsed/refractory multiple myeloma (MM).
    Raza, SN
    Veksler, Y
    Sabir, T
    Li, ZJ
    Anderson, L
    Jagannath, S
    BLOOD, 2000, 96 (11) : 168A - 169A
  • [2] Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM).
    Rajkumar, SV
    Dispenzieri, A
    Lacy, M
    Geyer, S
    Iturria, N
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, R
    Greipp, PR
    Gertz, MA
    Witzig, TE
    BLOOD, 2001, 98 (11) : 162A - 163A
  • [3] Thalidomide treatment of resistant or relapsed multiple myeloma patients
    Hus, M
    Dmoszynska, A
    Soroka-Wojtaszko, M
    Jawniak, D
    Legiec, W
    Ciepnuch, H
    Hellmann, A
    Wolska-Smolen, T
    Skotnicki, A
    Manko, J
    HAEMATOLOGICA, 2001, 86 (04) : 404 - 408
  • [4] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [5] Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Kumar, S
    Gertz, MA
    Dispenzieri, A
    Lacy, MQ
    Geyer, SM
    Iturria, NL
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, RA
    Greipp, PR
    Witzig, TE
    Rajkumar, SV
    MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 34 - 39
  • [6] Analysis of durability of response to thalidomide treatment for relapsed myeloma patients
    Myers, B
    Dolan, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (01) : 347 - 347
  • [7] Long term response and survival after thalidomide in relapsed/wrefractory multiple myeloma
    Zappasodi, P.
    Corso, A.
    Barbarano, L.
    Brasca, P.
    Petrucci, M. T.
    Calabrese, E.
    Palumbo, A.
    Bringhen, S.
    Pascutto, C.
    Mangiacavalli, S.
    Varettoni, M.
    Pica, G. M.
    Lazzarinu, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 137 - 137
  • [8] Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD).
    Srkalovic, G
    Karam, MA
    Trebisky, BM
    Hussein, MA
    BLOOD, 2000, 96 (11) : 294B - 295B
  • [9] PROGNOSTICATION OF RESPONSE TO BORTEZOMIB, PROGRESSION FREE AND OVERALL SURVIVAL IN RELAPSED/REFRACTORY MYELOMA PATIENTS
    Kyrtsonis, M. C.
    Vassilakopoulos, T. P.
    Sachanas, S.
    Panagoulias, G.
    Bartzis, V.
    Anargyrou, K.
    Dimou, M.
    Tzenou, T.
    Masouridis, S.
    Kalpadakis, C.
    Dimitrakopoulou, E.
    Kokoris, S. I.
    Dimitriadou, E.
    Siakantaris, M. P.
    Angelopoulou, M. K.
    Panayiotidis, P.
    Pangalis, G. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 263 - 263
  • [10] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Manier, Salomon
    Lam, Annette
    Roccia, Tito
    Schecter, Jordan M.
    Cost, Patricia
    Pacaud, Lida
    Poirier, Abbey
    Tremblay, Gabriel
    Lan, Tommy
    Valluri, Satish
    Kumar, Shaji
    BMC CANCER, 2024, 24 (01)
12345